Paper28301271
Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016).
Lai Y and 7 others. Hum Vaccin Immunother, 2017. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). Papers, record 28301271. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28301271
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016).
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Bibliometrics | Major topic |
| Drug Discovery | Major topic |
| Immunologic Factors | Major topic |
| Animals | |
| Biomedical Research | |
| Humans |
Source PubMed
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25285786 | Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. | BMC Med | 2014 | https://conductscience.org/library/papers/25285786 | PubMed |
| 2 | 12778055 | Development of potent monoclonal antibody auristatin conjugates for cancer therapy. | Nat Biotechnol | 2003 | https://conductscience.org/library/papers/12778055 | PubMed |
| 3 | 12047962 | Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. | Lancet | 2002 | https://conductscience.org/library/papers/12047962 | PubMed |
| 4 | 5432063 | Cleavage of structural proteins during the assembly of the head of bacteriophage T4. | Nature | 1970 | https://conductscience.org/library/papers/5432063 | PubMed |
| 5 | 3756930 | Production and characterization of two human glioma xenograft-localizing monoclonal antibodies. | Cancer Res | 1986 | https://conductscience.org/library/papers/3756930 | PubMed |
| 6 | 8194690 | Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. | Gastroenterology | 1994 | https://conductscience.org/library/papers/8194690 | PubMed |
| 7 | 15175435 | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15175435 | PubMed |
| 8 | 12584368 | Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. | N Engl J Med | 2003 | https://conductscience.org/library/papers/12584368 | PubMed |
| 9 | 7471090 | Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. | Cancer Res | 1980 | https://conductscience.org/library/papers/7471090 | PubMed |
| 10 | 20068188 | Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. | Cancer Res | 2010 | https://conductscience.org/library/papers/20068188 | PubMed |
| 11 | 8011287 | Making antibodies by phage display technology. | Annu Rev Immunol | 1994 | https://conductscience.org/library/papers/8011287 | PubMed |
| 12 | 16472588 | Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. | Gastroenterology | 2006 | https://conductscience.org/library/papers/16472588 | PubMed |
| 13 | 16904789 | Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. | Adv Drug Deliv Rev | 2006 | https://conductscience.org/library/papers/16904789 | PubMed |
| 14 | 3102250 | The use of hybrid hybridomas to target human cytotoxic T lymphocytes. | Eur J Immunol | 1987 | https://conductscience.org/library/papers/3102250 | PubMed |
| 15 | 8159246 | Antigen-specific human antibodies from mice comprising four distinct genetic modifications. | Nature | 1994 | https://conductscience.org/library/papers/8159246 | PubMed |
| 16 | 25077605 | Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014). | Expert Opin Biol Ther | 2014 | https://conductscience.org/library/papers/25077605 | PubMed |
| 17 | 9321530 | A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | N Engl J Med | 1997 | https://conductscience.org/library/papers/9321530 | PubMed |
| 18 | 23438745 | Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. | Chem Biol | 2013 | https://conductscience.org/library/papers/23438745 | PubMed |
| 19 | 23678006 | Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. | Blood | 2013 | https://conductscience.org/library/papers/23678006 | PubMed |
| 20 | 25568796 | The history of monoclonal antibody development - Progress, remaining challenges and future innovations. | Ann Med Surg (Lond) | 2014 | https://conductscience.org/library/papers/25568796 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39152301 | Immunotherapy for small cell lung cancer: the current state and future trajectories. | Discov Oncol | 2024 | https://conductscience.org/library/papers/39152301 | PubMed |
| 36568760 | Bibliometric and visual analysis of cardiovascular diseases and COVID-19 research. | Front Public Health | 2022 | https://conductscience.org/library/papers/36568760 | PubMed |
| 36137125 | Bibliometric analysis of hotspots and frontiers in cancer-related fatigue among ovarian cancer survivors. | PLoS One | 2022 | https://conductscience.org/library/papers/36137125 | PubMed |
| 33628140 | Technological Advancements in Monoclonal Antibodies. | ScientificWorldJournal | 2021 | https://conductscience.org/library/papers/33628140 | PubMed |
| 33363597 | A new era for monoclonal antibodies with applications in neurology (Review). | Exp Ther Med | 2021 | https://conductscience.org/library/papers/33363597 | PubMed |
| 33194520 | Comparative analytical profiling of bevacizumab biosimilars marketed in India: a national control laboratory study. | 3 Biotech | 2020 | https://conductscience.org/library/papers/33194520 | PubMed |
| 31483112 | Western Blotting with Solutions containing Nanoliter Volumes of Antibody. | Curr Protoc Cell Biol | 2019 | https://conductscience.org/library/papers/31483112 | PubMed |
| 30539362 | Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. | BioDrugs | 2019 | https://conductscience.org/library/papers/30539362 | PubMed |
| 29293380 | Trends involving monoclonal antibody (mAb) research and commercialization: A scientometric analysis of IMS Lifecycle R&D Focus Database (1980-2016). | Hum Vaccin Immunother | 2018 | https://conductscience.org/library/papers/29293380 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28301271
GET https://conductscience.org/api/papers/v1/28301271/references?page=2